The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Southern District of California on behalf of shareholders of Capricor Therapeutics, Inc. who purchased Securities between December 17, 2025 and July 29, 2026.
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company adopted changes to the pre-specified statistical analysis plan used to analyze clinical data for it's lead product candidate, Deramiocel; (2) the FDA had not agreed to those changes before the Company resubmitted the Deramiocel BLA; (3) as a result, there was a significant risk that the FDA could conclude the clinical results did not provide substantial evidence of effectiveness of Deramiocel; (4) as a result of the foregoing, there was a substantial risk to regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until September 28, 2026 to request that the court appoint them lead plaintiff.
To receive more information, please fill out the form.
